Novartis’ Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
Novartis AG (NYSE:NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of…
Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters
Bristol Myers Squibb Co (NYSE:BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments…
Why Adamis Shares Are Ripping Higher Today
Shares of Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) spiked higher in afternoon trading Thursday following some positive tidings on one of its pipeline assets.
Could Clovis Oncology Stock Be Gearing Up For Its Next Move?
Clovis Oncology Inc. (NASDAQ: CLVS) is gearing up to present this week at the American Society of Clinical Oncology annual meeting, which runs June 4-8.
The company is expected to report updated Phase 1b results on Lucitanib and Opdivo in patients with advanced solid tumors.
Ascendis Pharma’s VISEN Says Has Received Investigational New Drug Approval From Center For Drug Evaluation Of National Medical Products Administration For Phase 3 China Clinical Trial Of TransCon PTH Solution For Injection
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center
Actinium Pharmaceuticals Details SIERRA at Benzinga Global Small Cap Business Conference
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company that develops antibody radiation-conjugates (ARC), took part in the Benzinga Global Small Cap Business Conference on May 13, 2021.
Merck Completes Women’s Health Organon Spinoff
In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women’s health business into a standalone spinoff.
Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic Keratopathy
Oyster Point Pharma Inc (NASDAQ:OYST) has announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene…
Histogen Stops HST 001 Development After Trial Failure, Shifts Focus On Programs For Orthopedic Indications
Histogen Inc (NASDAQ:HSTO) has decided to suspend the development of the HST 001 program after taking into consideration the results from…